A Phase 2a Crossover Trial Evaluating the Safety of and Adherence to a Vaginal Matrix Ring Containing Dapivirine and Oral Emtricitabine/Tenofovir Disoproxil Fumarate in an Adolescent and Young Adult Female Population
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 12 Sep 2017
At a glance
- Drugs Dapivirine (Primary) ; Emtricitabine/tenofovir disoproxil fumarate (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions
- Acronyms REACH
- 05 Sep 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 28 Jun 2017 Planned initiation date changed from 1 Apr 2017 to 1 Nov 2017.
- 14 Mar 2017 New trial record